Bordetella Pertussis, Whooping Cough Clinical Trial
— PERT-SEVEREIIOfficial title:
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
The resurgence of pertussis is associated with an evolutionary mechanism under the pressure of current acellular vaccines, with a possible impact on vaccine effectiveness and disease expression. Little is known about the mechanisms involved in the clinical variability of pertussis, including its most severe malignant form observed in infants (mortality between 50-80%). The main challenges are: (i) the lack of knowledge about the gene expression of B. pertussis strains currently circulating during human infection, incorporating evolutionary changes and vaccine-induced selective pressure; (ii) the poor understanding of the variability in clinical expression of pertussis, and (iii) the lack of biomarkers to predict disease severity or prognosis in infants. An integrative strategy combining a clinical, microbiological, immunological and 'omic' approach from a prospective cohort of children with pertussis will be used to identify 1. 'in situ' expression profiles of B. pertussis genes and proteins incorporating recent evolutionary changes and 2. a systemic and respiratory immune signature in B. pertussis-infected children according to severity. Results should furthermore serve as a prerequisite for the identification of severity biomarkers and new vaccine antigen candidates taking into account specific immune responses in infants.
Status | Recruiting |
Enrollment | 210 |
Est. completion date | November 16, 2026 |
Est. primary completion date | November 16, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 15 Years |
Eligibility | Inclusion Criteria: - be between the ages of 0 and 15 years inclusive - be suspected of having pertussis by the physician in charge, with the prescription of a diagnostic PCR (pertussis PCR, which may be a syndromic PCR, a PCR targeting IS481 and/or IS1001) - be free of any pathology/treatment that may influence the immune response (autoimmune/inflammatory pathology or immune deficiency not listed above, hepatic insufficiency, taking immunosuppressive treatment (including taking oral corticosteroids with a dose = 10 mg/d Prednisone equivalent for more than 15 days) - Have received age-appropriate information and written assent or consent from their parents/legal guardians - be affiliated with or benefiting from a social security plan Exclusion Criteria: - Patient with any pathology/treatment that may influence the immune response (autoimmune/inflammatory pathology or immune deficiency not listed above, hepatic failure, taking immunosuppressive therapy (including oral corticosteroids with dose = 10 mg/d prednisone equivalent for more than 15 days) - Use of antibiotics active against pertussis in the 24 hours preceding the sampling - Delay between the result of the diagnostic sample (pertussis PCR) and the day of inclusion > 48 hours - Patient's condition that, in the opinion of the physician, is incompatible with the expanded/additional sampling(s) required by the study - Infant with a weight < 2.5 kg at the time of inclusion. |
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeaux | Bordeaux | |
France | Hôpital Louis Mourier | Colombes | |
France | Centre hospitalier intercommunal de Créteil | Créteil | |
France | Hôpital Roger Salengo | Lille | |
France | Hospices Civils de Lyon | Lyon | |
France | Hôpital de la Timone Enfants, APHM | Marseille | |
France | Hôpital Nord, APHM | Marseille | |
France | CHU de Nantes | Nantes | |
France | CHU Armand Trousseau | Paris | |
France | Hopital Necker | Paris | |
France | Hôpital Robert Debré | Paris | |
France | CHU Rouen | Rouen | |
France | Réseau ACTIV | Saint-Maur-des-Fossés | |
France | CHU de Toulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Institut Pasteur | Centre Hospitalier Intercommunal Creteil, CHR - Hôpital Roger Salengo, Hôpital Armand Trousseau, Hôpital de la Timone, Hôpital Louis Mourier, Hôpital Necker-Enfants Malades, Hôpital Nord - APHM, Hopital Universitaire Robert-Debre, Hospices Civils de Lyon, Nantes University Hospital, Réseau ACTIV, University Hospital, Bordeaux, University Hospital, Rouen, University Hospital, Toulouse |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of expression level of Bp genes during infection by Nanostring transcriptomic analysis of Bp isolates from the nasopharynx of children with pertussis. | To identify in a standardized way the microbial "in situ" expression profiles of currently circulating Bp genes during infection in children ; | 3 years | |
Primary | Measurement of plasma cytokine and chemokine concentrations by SIMOA digital ELISA | To determine systemic and respiratory immune responses in children during pertussis. | 3 years | |
Primary | Phenotyping of immune cells by cytometry with a 20-color flow cytometry panel | To determine systemic and respiratory immune responses in children during pertussis. | 3 years | |
Secondary | Measurement of expression level of Bp genes which is modified by recent gene developments related to vaccine pressure by Nanostring transcriptomic analysis of Bp isolates | List of microbial genes which expression is modified by recent genomic developments related to vaccine pressure | 3 years | |
Secondary | Measurement of high expression level of Bp genes in all clinical forms of pertussis by Nanostring transcriptomic analysis of Bp isolates | To identify new candidate Bp genes for a future protein vaccine | 3 years | |
Secondary | Measurement of expression level of Bp genes which is associated with severe pertussis by Nanostring transcriptomic analysis of Bp isolates | List of virulence genes differentially expressed during severe pertussis | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05116241 -
Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
|
Phase 2 | |
Completed |
NCT03197597 -
EUpertstrain 4 Study of Bordetella Pertussis Isolates
|
N/A | |
Completed |
NCT05461131 -
Pertussis Challenge Study in Adults Vaccinated With BPZE1
|
Phase 2 | |
Completed |
NCT02983487 -
Pertussis Immunization Programs in Low Income Countries
|
||
Completed |
NCT03388034 -
Pertussis Immunization Programs in Low Income Countries - Ivory Coast
|